The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
1 to 10 of 2205    Next 10 >    Last >>
Add to Report ID Question Status Last Updated
20200042

Solid Tumor Rules (2018)/Histology--Brain and CNS: How is the histology coded when the diagnosis comment for a posterior fossa tumor resection states:  Taken together, these findings are indicative of medulloblastoma with extensive nodularity? See Discussion.

Final Aug 25 2020
20200041

Reportability--Brain and CNS: Is an intradural T12/L1 capillary hemangioma reportable? See Discussion.

 

Final Aug 18 2020
20200040

Reportability--Skin:  Is pseudomyogenic hemangioendothelioma (PMH) reportable with morphology code 9133/3?  See Discussion.

Final Aug 17 2020
20200038

Solid Tumor Rules (2018)/Histology--Lung:  Can the stated histology from a biomarker/immunohistochemistry (IHC) report be used for coding histology? See Discussion.

Final Jul 29 2020
20200036

Reportability--Skin:  Is malignant proliferative trichilemmal tumor (PTT) reportable, and if so, do we apply the matrix rule and code it to 8103/3? A literature search reveals these do exist, but are extremely rare.

Final Jul 24 2020
20200035

Reportability/Ambiguous Terminology--Brain and CNS:  Is the expression differential considerations a synonym for differential diagnoses? See Discussion.

Final Jul 20 2020
20200034

Solid Tumor Rules (2018)/Histology--Breast: How should histology be coded for 2020 breast lumpectomy final diagnosis of invasive ductal carcinoma?  Summary Cancer Data and CAP Summary states: Invasive carcinoma with the following features: Histologic type: Tubular adenocarcinoma. See Discussion.

Final Jul 20 2020
20200033

Solid Tumor Rules (2018)/Multiple primaries--Breast: How many primary tumors should be abstracted for a 2018 breast excision with a final diagnosis of invasive mucinous adenocarcinoma (0.7 cm) with ductal carcinoma in situ (DCIS) present as discontinuous foci, spanning 12 cm? See Discussion.
 

Final Jul 20 2020
20200032

Date of Diagnosis--Brain and CNS: How is the Date of Diagnosis coded when an MRI clinically diagnoses a borderline brain tumor on 4/4/2020, but the subsequent biopsy pathologically diagnoses a malignant brain tumor on 5/20/2020? See Discussion.

Final Jul 10 2020
20200030

Solid Tumor Rules/Multiple primaries--Lung: How many primaries should be accessioned for the following patient scenario?
1) 09/2014 Left upper lobe (LUL), unifocal, localized acinar adenocarcinoma (8550/3) treated with lobectomy.
2) 04/2016 Right lower lobe (RLL), unifocal, localized acinar adenocarcinoma (8550/3) treated with wedge resection.
3) 04/2019 (within 3 years, but masked full date) Left lower lobe (LLL), unifocal, non-small cell carcinoma (8046/3) with brain metastasis. See Discussion.

Final Jul 06 2020
Next 10 >